Long-Term Results up to 12 Months After Catheter-Based Alcohol-Mediated Renal Denervation for Treatment of Resistant Hypertension

Felix Mahfoud, Horst Sievert, Stefan Bertog, Lucas Lauder, Sebastian Ewen, Jean-Philippe Lengelé, Wojciech Wojakowski, Roland Schmieder, Markus van der Giet, Michael A Weber, David E Kandzari, Helen Parise, Tim A Fischell, Atul Pathak, Alexandre Persu, Felix Mahfoud, Horst Sievert, Stefan Bertog, Lucas Lauder, Sebastian Ewen, Jean-Philippe Lengelé, Wojciech Wojakowski, Roland Schmieder, Markus van der Giet, Michael A Weber, David E Kandzari, Helen Parise, Tim A Fischell, Atul Pathak, Alexandre Persu

Abstract

[Figure: see text].

Trial registration: ClinicalTrials.gov NCT02570113.

Keywords: alcohol; denervation; hypertension; renal artery.

Figures

Figure 1.
Figure 1.
Schematic of the flow of patient enrollment and follow-up. Flow diagram showing the flow of patients in the clinical trial through the selection process, treatment, and follow-up. *One patient returned for the 12-mo visit but was unable to complete efficacy assessments due to an adverse event (cerebrovascular accident). Note that the number of patients with valid ambulatory blood pressure measurement (ABPM) data at 12 mo is N=38 for 24-h and nighttime ABPM and N=39 for daytime ABPM.
Figure 2.
Figure 2.
Ambulatory and office blood pressure results at 1-, 3-, 6-, and 12-mo follow-up. Mean reductions in (A) 24-h ambulatory systolic blood pressure (ASBP) and diastolic blood pressure over time and (B) office systolic blood pressure (OSBP) and diastolic blood pressure over time. Note: all differences from baseline were statistically significant at P<0.05.
Figure 3.
Figure 3.
Twelve-month follow-up of ambulatory blood pressure. Mean decrease in 24-h mean, daytime, and nighttime ambulatory systolic blood pressure (A) and ambulatory diastolic blood pressure at 12 mo (B). Note: all differences from baseline were statistically significant at P<0.05. Note: the number of patients with valid ambulatory blood pressure data at 12 mo is N=38 for 24-h and nighttime results and N=39 for daytime results.
Figure 4.
Figure 4.
Hourly ambulatory blood pressure at baseline and 6 and 12 mo.A, Hourly ambulatory systolic blood pressure (ASBP); (B) hourly ambulatory diastolic blood pressure (ADBP). Note: the number of patients with valid ambulatory blood pressure data at 12 mo is N=38 for 24-h and nighttime results and N=39 for daytime results.

References

    1. Doumas M, Faselis C, Papademetriou V. Renal sympathetic denervation and systemic hypertension. Am J Cardiol. 2010;105:570–576. doi: 10.1016/j.amjcard.2009.10.027
    1. Mahfoud F, Böhm M, Azizi M, Pathak A, Durand Zaleski I, Ewen S, Tsioufis K, Andersson B, Blankestijn PJ, Burnier M, et al. . Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. Eur Heart J. 2015;36:2219–2227. doi: 10.1093/eurheartj/ehv192
    1. Lauder L, Azizi M, Kirtane AJ, Böhm M, Mahfoud F. Device-based therapies for arterial hypertension. Nat Rev Cardiol. 2020;17:614–628. doi: 10.1038/s41569-020-0364-1
    1. Mahfoud F, Schlaich M, Böhm M, Esler M, Lüscher TF. Catheter-based renal denervation: the next chapter begins. Eur Heart J. 2018;39:4144–4149. doi: 10.1093/eurheartj/ehy584
    1. Böhm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, Tsioufis K, Pocock S, Konstantinidis D, Choi JW, et al. ; SPYRAL HTN-OFF MED Pivotal Investigators. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395:1444–1451. doi: 10.1016/S0140-6736(20)30554-7
    1. Kandzari DE, Böhm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, Tsioufis K, Tousoulis D, Choi JW, East C, et al. ; SPYRAL HTN-ON MED Trial Investigators. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391:2346–2355. doi: 10.1016/S0140-6736(18)30951-6
    1. Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Lobo MD, Sharp ASP, Bloch MJ, Basile J, Wang Y, et al. . Six-month results of treatment-blinded medication titration for hypertension control following randomization to endovascular ultrasound renal denervation or a sham procedure in the RADIANCE-HTN SOLO trial. Circulation. 2019;139:2542–2553. doi: 10.1161/CIRCULATIONAHA.119.040451
    1. Fischell TA, Ebner A, Gallo S, Ikeno F, Minarsch L, Vega F, Haratani N, Ghazarossian VE. Transcatheter alcohol-mediated perivascular renal denervation with the Peregrine System: first-in-human experience. JACC Cardiovasc Interv. 2016;9:589–598. doi: 10.1016/j.jcin.2015.11.041
    1. Bertog S, Fischel TA, Vega F, Ghazarossian V, Pathak A, Vaskelyte L, Kent D, Sievert H, Ladich E, Yahagi K, et al. . Randomised, blinded and controlled comparative study of chemical and radiofrequency-based renal denervation in a porcine model. EuroIntervention. 2017;12:e1898–e1906. doi: 10.4244/EIJ-D-16-00206
    1. Fischell TA, Vega F, Raju N, Johnson ET, Kent DJ, Ragland RR, Fischell DR, Almany SL, Ghazarossian VE. Ethanol-mediated perivascular renal sympathetic denervation: preclinical validation of safety and efficacy in a porcine model. EuroIntervention. 2013;9:140–147. doi: 10.4244/EIJV9I1A20
    1. Mahfoud F, Renkin J, Sievert H, Bertog S, Ewen S, Böhm M, Lengelé JP, Wojakowski W, Schmieder R, van der Giet M, et al. . Alcohol-mediated renal denervation using the Peregrine System Infusion Catheter for treatment of hypertension. JACC Cardiovasc Interv. 2020;13:471–484. doi: 10.1016/j.jcin.2019.10.048
    1. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, et al. . Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403–1419. doi: 10.1161/HYPERTENSIONAHA.108.189141
    1. Kario K, Böhm M, Mahfoud F, Townsend RR, Weber MA, Patel M, Tyson CC, Weil J, Agdirlioglu T, Cohen SA, et al. . Twenty-four-hour ambulatory blood pressure reduction patterns after renal denervation in the SPYRAL HTN-OFF MED trial. Circulation. 2018;138:1602–1604. doi: 10.1161/CIRCULATIONAHA.118.035588
    1. Whelton PK, Carey RM, Aronow WS, Casey DE, Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, et al. . 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018;138:e426–e483. doi: 10.1161/CIR.0000000000000597
    1. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957–967. doi: 10.1016/S0140-6736(15)01225-8
    1. Mahfoud F, Böhm M, Schmieder R, Narkiewicz K, Ewen S, Ruilope L, Schlaich M, Williams B, Fahy M, Mancia G. Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. Eur Heart J. 2019;40:3474–3482. doi: 10.1093/eurheartj/ehz118
    1. Mahfoud F, Mancia G, Schmieder R, Narkiewicz K, Ruilope L, Schlaich M, Whitbourn R, Zirlik A, Zeller T, Stawowy P, et al. . Renal denervation in high-risk patients with hypertension. J Am Coll Cardiol. 2020;75:2879–2888. doi: 10.1016/j.jacc.2020.04.036
    1. Mahfoud F, Azizi M, Ewen S, Pathak A, Ukena C, Blankestijn PJ, Böhm M, Burnier M, Chatellier G, Durand Zaleski I, et al. . Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in device-based hypertension therapies. Eur Heart J. 2020;41:1588–1599. doi: 10.1093/eurheartj/ehaa121
    1. Janas A, Król M, Hochuł M, Jochymczyk M, Hayward-Costa C, Parise H, Haratani N, Fischell T, Wojakowski W. Evaluation of transcatheter alcohol-mediated perivascular renal denervation to treat resistant hypertension. J Clin Med. 2020;9:E1881. doi: 10.3390/jcm9061881
    1. Weinstein JR, Anderson S. The aging kidney: physiological changes. Adv Chronic Kidney Dis. 2010;17:302–307. doi: 10.1053/j.ackd.2010.05.002
    1. Persu A, Kjeldsen S, Staessen JA, Azizi M. Renal denervation for treatment of hypertension: a second start and new challenges. Curr Hypertens Rep. 2016;18:6. doi: 10.1007/s11906-015-0610-9
    1. Mahfoud F, Weber M, Schmieder RE, Lobo MD, Blankestijn PJ, Persu A, Fischell TA, Parise H, Pathak A, Kandzari DE.Catheter-based alcohol-mediated renal denervation for the treatment of uncontrolled hypertension: design of two sham-controlled, randomized, blinded trials in the absence (TARGET BP OFF-MED) and presence (TARGET BP I) of antihypertensive medications. Am Heart J. 2021;239:90–99. doi: 10.1016/j.ahj.2021.05.015

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren